Talecris Biotherapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Talecris Biotherapeutics's estimated annual revenue is currently $76.6M per year.
- Talecris Biotherapeutics's estimated revenue per employee is $155,000
Employee Data
- Talecris Biotherapeutics has 494 Employees.
- Talecris Biotherapeutics grew their employee count by 1% last year.
Talecris Biotherapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11.2M | 72 | -13% | N/A | N/A |
#2 | $5099.8M | 32902 | -4% | N/A | N/A |
#3 | $1.7M | 11 | 0% | N/A | N/A |
#4 | $0.6M | 4 | -56% | N/A | N/A |
#5 | $0.9M | 11 | -39% | N/A | N/A |
#6 | $1.7M | 11 | 10% | N/A | N/A |
#7 | $0.6M | 4 | -33% | N/A | N/A |
#8 | $4.8M | 31 | -6% | N/A | N/A |
#9 | $6.4M | 41 | 3% | N/A | N/A |
#10 | $4.2M | 27 | -18% | N/A | N/A |
What Is Talecris Biotherapeutics?
We are a biopharmaceutical company that is one of the largest producers and marketers of plasma-derived protein therapies in the world. We develop, produce, market, and distribute therapies that extend and enhance the lives of people suffering from chronic and acute, often life-threatening, conditions, such as chronic inflammatory demyelinating polyneuropathy (CIDP), primary immune deficiencies (PI), alpha-1 antitrypsin deficiency, bleeding disorders, infectious diseases and severe trauma. Our products are derived from human plasma, the liquid component of blood, which is sourced from our plasma collection centers or purchased from third parties, located in the United States.
keywords:N/A
N/A
Total Funding
494
Number of Employees
$76.6M
Revenue (est)
1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Talecris Biotherapeutics News
Baxter, Kamada, Talecris Biotherapeutics, Aventis Behring. Le «Global Inhibiteur de l'alpha1-protéinase Market Research Report» est une...
... Stiftung ehemals Bündner Heilstätten, SUVA, Freiwillige Akademische Gesellschaft, UBS Wealth Foundation, Talecris Biotherapeutics GmbH,...
The FTC had been concerned that a merger of two of the top companies in the specialized blood therapeutics space would hurt competition and lead to higher drug costs for patients. The FTC raised antitrust concerns in 2009 when it blocked a proposed $3.1 billion acquisition of Talecris by CSL Ltd ...
The consent agreement is still subject to approval by FTC commissioners. FTC officials had been concerned that the acquisition of Research Triangle Park, North Carolina-based Talecris would reduce competition and raise prices for drugs in the blood therapeutics market. To satisfy FTC concerns, ...
(UPDATED: See below.) Is the air starting to hiss out of the private-equity bubbble? Looking at Talecris Biotherapeutics, a stodgy biotech controlled by private-equity firms Cerberus Capital Management and Ampersand Ventures that filed to raise as much as $1 billion in an initial offering last F ...
Other Companies in Durham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $86.8M | 526 | 14% | $852M |
#2 | $109M | 545 | 64% | N/A |
#3 | $150.2M | 546 | 6% | N/A |
#4 | $146.7M | 550 | 4% | N/A |
#5 | $160.2M | 562 | 49% | N/A |